Peregrine Pharmaceuticals, Inc. - Bavituximab Anti-Viral

Bavituximab Anti-Viral

Bavituximab Anti-Viral represents a unique approach to treating viral diseases by recognizing features found only on infected cells and enveloped viruses. Bavituximab is a monoclonal antibody that binds to a basic component of the cell structure called an aminophospholipid that is exposed on the surface of cells only when they are infected with certain viruses or when they are malignant.

After binding to these infected cells, the drug alerts the body’s immune system to attack the infected cells. This makes infected cells particularly susceptible to bavituximab treatment, while potentially sparing healthy cells. Also, bavituximab binds to phospholipids which are derived from the host (human) cell and not the virus, which indicates it may not be susceptible to viral drug resistance. In addition to treating an active illness, bavituximab may also confer long-term immunity. For more scientific information about bavituximab anti-viral, click here.

Hepatitis C Clinical Program. According to the World Health Organization, an estimated 170 million people are chronically infected with hepatitis C virus (HCV) globally. HCV is a major cause of acute hepatitis and chronic liver disease and is the leading cause of liver transplantation in the United States.

Peregrine has completed single and multiple ascending dose, monotherapy trials in patients with chronic HCV infection. Bavituximab infusion was generally well-tolerated and encouraging signs of anti-viral activity were seen at all dose levels tested. A Phase Ib study in patients co-infected with HCV and Human Immunodeficiency Virus (HIV) is now underway. This multi-center trial is designed to evaluate multiple doses of bavituximab for safety, pharmacokinetics and initial efficacy.

In pre-clinical experiments, Peregrine continues to evaluate bavituximab's potential for the treatment of several virus infections including influenza and HIV.

If you are a health care provider interested in referring a patient or learning more about these clinical trials, please send an email correspondence to Peregrine Pharmaceuticals at This e-mail address is being protected from spam bots, you need JavaScript enabled to view it or visit ClinicalTrials.gov.

If you are a patient interested in participating in one of these trials, please have your personal physician send an email correspondence to Peregrine.